Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Cardiff Oncology, Inc.NASDAQ: CRDF

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital growth accelerates

Q1 FY2026 change in working capital of $1.73M (cash outflow) rose 112.1% year over year, ahead of the -13.9% change in trailing-twelve-month change in working capital. Sequentially, it rose 2148.1% from the prior quarter.

Context

  • Change in working capital amounted to 367.5% of revenue in FY2025, down 97.0 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +112.1% holds above the trailing-twelve-month pace of -13.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.73M+2148.1% QoQ
Last fiscal yearDec 2025
$2.18M-31.3% YoY
LTMMar 2026
$994K-13.9% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+112.1%——
1 year-31.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
2.18M USD
Year-over-year change
-31.3%

Change in Working Capital vs competitors

How CRDF compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13.9% is the 5th highest of 9, against a peer median of -19.3%.
  • Change in working capital amounts to 189.3% of revenue for CRDF, versus a peer median of 188.4%.
CRDF Competitors
Change in Working Capital for CRDF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PEPGPepGen Inc.LTM Mar 2026$13.38M USD-256.4%——
IPHAInnate Pharma S.A.FY2025€10.21M EUR-126.1%-6.5%366.4%
FBRXForte Biosciences, Inc.LTM Mar 2026$7.6M USD+32.9%+89.2%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$5.97M USD+455.6%+139.1%188.4%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$5.82M USD+238.7%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026$5.12M USD-180.4%+184.2%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$2.6M USD-71.5%—146.0%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.53M CHF+140.6%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$994K USD-13.9%—189.3%
Peer median (excluding CRDF) —-19.3%+114.2%188.4%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Depreciation & Amortization451K236K398K404K904K
Deferred Income Tax1.32M0000
Stock-Based Compensation3.23M4.26M4.51M4.76M5.69M
Change in Working Capital(1.79M)(380K)6.57M3.17M2.18M
Accounts Receivables(215K)(236K)483K(484K)591K
Inventory00000
Accounts Payables719K1.35M2.83M2.99M2.2M
Other Working Capital(2.29M)(1.49M)3.25M671K(614K)
Other Non-Cash Items2.03M772K(921K)(598K)(848K)
Operating Cash Flow(23.04M)(33.82M)(30.89M)(37.69M)(37.92M)
Capital Expenditures(205K)(892K)(582K)(80K)(44K)
Acquisitions (Net)205K(114K)000
Purchases of Investments(174.39M)(91.23M)(70.08M)(23.56M)(71.12M)
Sales of Investments43.14M130.27M106.86M37.37M73.25M
Other Investing Activities(205K)114K00(744K)
Investing Cash Flow(131.45M)38.15M36.2M13.73M1.34M
Debt Repayment00000
Common Stock Issued34.19M75K053.41M2.58M
Common Stock Repurchased00000
Dividends Paid(24K)(414K)000
Other Financing Activities1.29M414K0373K0
Financing Cash Flow35.45M75K053.78M2.58M
Effect of Forex Changes00000
Net Change in Cash(119.04M)4.4M5.31M29.82M(34M)
Free Cash Flow(23.25M)(34.71M)(31.47M)(37.77M)(37.97M)

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.